This collaboration with Astellas could significantly enhance Poseida Therapeutics' position in the oncology sector, potentially leading to increased investor confidence and a positive impact on its stock price in the short term. The partnership leverages Poseida's proprietary technology, indicating a strong validation of its platform and potential for future revenue through development milestones and royalties.